HeartBeam Inc. (NASDAQ: BEAT) has achieved a significant turning point following FDA clearance of its 12-lead ECG synthesis software in December 2025 for arrhythmia assessment, according to a recent article. The clearance resolved an earlier regulatory setback and allowed the company to transition to commercial-stage status. Joseph Gunnar & Co. subsequently upgraded the company from Hold to Buy and raised its 12-month price target to $4 from $1, citing regulatory progress and the transition toward commercialization.
"We upgrade HeartBeam to a BUY and High-Risk rating with a raised price target of $4 (from $1), reflecting progress in cardiac risk detection," the February 2026 report states. The article highlights that the FDA clearance and analyst upgrade mark a pivotal moment for HeartBeam, which is developing the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions.
HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company's platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement.
The full article is available at https://ibn.fm/NrrYt. For more information about HeartBeam, visit www.HeartBeam.com. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
